+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Induced Pluripotent Stem Cells: Global Markets

  • ID: 4912137
  • Report
  • January 2020
  • Region: Global
  • 143 Pages
  • BCC Research
UP TO OFF until Jun 30th 2022

FEATURED COMPANIES

  • Addgene
  • Bio-Techne
  • EMD Millipore
  • Invivogen
  • Opsis Therapeutics
  • Promega Corp.

Report Scope:

This study is focused on the market side of iPSCs rather than its technical side. Different market segments for this emerging market are covered. For example, application-based market segments include academic research, drug development and toxicity testing, and regenerative medicine; product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation and cell analysis; iPSC-derived cell-type-based market segments include cardiomyocytes, hepatocytes, neurons, endothelial cells and other cell types; geography-based market segments include the U.S., Europe, Asia-Pacific and Rest of the World. Research and market trends are also analyzed by studying the funding, patent publications and research publications in the field.

The Report Includes:


  • 59 tables
  • An overview of the global market for induced pluripotent stem cells
  • Analyses of global market trends with data from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
  • Information on induced pluripotent stem cell research products, including various assays and kits, culture media and medium components, such as serum, growth factors and inhibitors, antibodies, enzymes
  • Complete understanding of the key technologies adopted for induced pluripotent stem cell research
  • Discussion of important manufacturers, technologies, and factors influencing market demand, such as the driving forces and limiting factors of induced pluripotent stem cell market growth
  • Profiles of major players in the industry, including Applied StemCell Inc., BlueRock Therapeutics, Corning Life Sciences, EMD Millipore, Lonza Group Ltd., Promega Corp. and Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Addgene
  • Bio-Techne
  • EMD Millipore
  • Invivogen
  • Opsis Therapeutics
  • Promega Corp.

Chapter 1 Introduction
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Intended Audience
  • Scope of Report
  • Methodology
  • Information Sources
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports


Chapter 2 Summary and Highlights
  • Key Drivers for Market Growth


Chapter 3 Overview
  • Introduction
  • History and Current State
  • Evolution of Induced Pluripotent Stem Cell Research
  • Advantages and Disadvantages of Induced Pluripotent Stem Cells
  • Advantages
  • Disadvantages
  • Technology Overview
  • Induced Pluripotent Stem Cell Generation
  • Induced Pluripotent Stem Cell Differentiation
  • Current Challenges to iPSC Applications


Chapter 4 Induced Pluripotent Stem Cell Applications
  • Academic Research
  • Pharmaco-Toxicological Screening
  • Drug Discovery and Development
  • Disease Modeling
  • Tissue Engineering
  • Cell Therapy


Chapter 5 Induced Pluripotent Stem Cell Market Segmentation and Forecast
  • Market Overview
  • Application-Based Market Overview
  • U.S. Induced Pluripotent Stem Cell Product Market
  • Induced Pluripotent Stem Cell-Derived Tissue Cell Market
  • Induced Pluripotent Stem Cell and Derivative Cell Market
  • Major Suppliers and Manufacturers of Induced Pluripotent Stem Cell Products
  • Market for Induced Pluripotent Stem Cell-Derived Cells by Application
  • Market for Induced Pluripotent Stem Cell by Product Function
  • Global Market
  • Regional Markets
  • Research Market Compared with the Clinical Market
  • Application-Based Markets for Induced Pluripotent Stem Cell-Derived Cells
  • Market for Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells
  • Market for Human Hepatocytes Derived from Induced Pluripotent Stem Cells
  • Market for Human Endothelia Cells Derived from Induced Pluripotent Stem Cells
  • Regional Markets
  • Market for Human Neural Cells Derived from Induced Pluripotent Stem Cells
  • Regional Markets
  • Induced Pluripotent Stem Cells and Their Derived Cells Market by Species
  • Global Market
  • Regional Markets
  • Induced Pluripotent Stem Cell Culture Markets


Chapter 6 Induced Pluripotent Stem Cell Research Application Market
  • Induced Pluripotent Stem Cell Research Product Types
  • Major Players
  • Major Commercial Entities
  • Major Non-Commercial Organizations
  • Market Shares and Projections


Chapter 7 Drug Discovery and Development Market
  • Product Types
  • Major Players
  • Market Shares and Projections


Chapter 8 Induced Pluripotent Stem Cell Contract Service Market
  • Induced Pluripotent Stem Cell Contract Service Types
  • Major Players
  • Market Shares and Projections


Chapter 9 Induced Pluripotent Stem Cell Clinical Application Market
  • Product Types
  • Regulations
  • Market Projection


Chapter 10 Research Market Trend Analysis
  • Grant Analysis
  • Patent Analysis
  • Scientific Publication Analysis
  • Driving Forces


Chapter 11 Clinical Application Market Trend Analysis
  • Clinical Trials
  • Age-Related Macular Degeneration
  • Ischemic Heart Disease
  • Parkinson's Disease
  • Graft-versus-Host Disease (GvHD)
  • Spine Cord Injuries
  • Cornea Repair
  • Cancers
  • Driving Forces
  • Limiting Factors
  • Technologies
  • Regulations
  • Market Acceptance
  • Clinical Efficiency


Chapter 12 Company Profiles
  • ABM (Applied Biological Materials Inc.)
  • Addgene
  • Allele Biotechnology And Pharmaceuticals Inc.
  • Alstem Llc
  • Applied Stemcell Inc.
  • ATCC
  • Axol Bioscience
  • Bio-Techne
  • Bluerock Therapeutics
  • Bristol-Myers Squibb (Ipierian)
  • Cell Signaling Technology
  • Cellular Dynamics International, A Fujifilm Company
  • Corning Life Sciences
  • Creative Bioarray
  • EMD Millipore
  • Fate Therapeutics
  • Genecopoeia
  • Gentarget Inc.
  • Id Pharma Co., Ltd.
  • Invivogen
  • Lonza Group Ltd.
  • Megakaryon Corp.
  • Mti-Globalstem, A Part Of Thermo Fisher Scientific
  • Ncardia
  • Newcells Biotech
  • Opsis Therapeutics
  • Orig3N Inc.
  • Peprotech
  • Plasticell Ltd.
  • Primorigen Biosciences
  • Promega Corp.
  • Promocell Gmbh
  • Qiagen N.V.
  • Reprocell Inc.
  • Roslin Cell Sciences
  • Sciencell Research Laboratories
  • Sigma-Aldrich, A Part Of Milliporesigma
  • Stemcell Technologies
  • Stemgent Inc., A Reprocell Group Co.
  • System Biosciences Inc.
  • Takara Bio Usa Inc. (Clontech Laboratories)
  • Thermo Fisher Scientific
  • Viacyte Inc.
  • Waisman Biomanufacturing


Chapter 13 Conclusions
List of Tables
Summary Table: Global Market for Induced Pluripotent Stem Cells, by Region, Through 2024
Table 1: U.S. Market for Induced Pluripotent Stem Cell Products, by U.S. State, Through 2024
Table 2: Global Market for the Generation of Induced Pluripotent Stem Cells, by Reprogramming Method, Through 2024
Table 3: Global Market for the Generation of Induced Pluripotent Stem Cells, by Method, Through 2024
Table 4: Global Market for Induced Pluripotent Stem Cell Products, by Application, Through 2024
Table 5: U.S. Market for Induced Pluripotent Stem Cell Products, by Application, Through 2024
Table 6: Global Market for Induced Pluripotent Stem Cell-Derived Tissue Cells, by Type, Through 2024
Table 7: Global Market for Induced Pluripotent Stem Cell-Derived Cells, by Species, Through 2024
Table 8: Major Commercial Suppliers of Induced Pluripotent Stem Cell Products, by Country, October 31, 2019
Table 9: Major U.S. Commercial Manufacturers of Induced Pluripotent Stem Cells, by Country, October 31, 2019
Table 10: Global Market for Induced Pluripotent Stem Cell-Derived Cells, by Application, Through 2024
Table 11: Global Market for Induced Pluripotent Stem Cell-Related Products, by Product Function, Through 2024
Table 12: U.S. Market for Induced Pluripotent Stem Cell-Related Products, by Product Function, Through 2024
Table 13: Global Market for Induced Pluripotent Stem Cells in Research and Clinical Uses, Through 2024
Table 14: Global Market for Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes, by Application, Through 2024
Table 15: U.S. Market for Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes, by Application, Through 2024
Table 16: European Market for Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes, by Application, Through 2024
Table 17: Asia-Pacific Market for Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes, by Application, Through 2024
Table 18: Global Market for Induced Pluripotent Stem Cell-Derived Human Hepatocytes, by Application, Through 2024
Table 19: U.S. Market for Induced Pluripotent Stem Cell-Derived Human Hepatocytes, by Application, Through 2024
Table 20: European Market for Induced Pluripotent Stem Cell-Derived Human Hepatocytes, by Application, Through 2024
Table 21: Asia-Pacific Market for Induced Pluripotent Stem Cell-Derived Human Hepatocytes, by Application, Through 2024
Table 22: Global Market for Induced Pluripotent Stem Cell-Derived Human Endothelia Cells, by Application, Through 2024
Table 23: U.S. Market for Induced Pluripotent Stem Cell-Derived Human Endothelia Cells, by Application, Through 2024
Table 24: European Market for Induced Pluripotent Stem Cell-Derived Human Endothelia Cells, by Application, Through 2024
Table 25: Asia-Pacific Market for Induced Pluripotent Stem Cell-Derived Human Endothelia Cells, by Application, Through 2024
Table 26: Global Market for Induced Pluripotent Stem Cell-Derived Human Neural Cells, by Application, Through 2024
Table 27: U.S. Market for Induced Pluripotent Stem Cell-Derived Human Neural Cells, by Application, Through 2024
Table 28: European Market for Induced Pluripotent Stem Cell-Derived Human Neural Cells, by Application, Through 2024
Table 29: Asia-Pacific Market for Induced Pluripotent Stem Cell-Derived Human Neural Cells, by Application, Through 2024
Table 30: Global Market for Induced Pluripotent Stem Cells and Derivative Cells, by Species, Through 2024
Table 31: U.S. Market for Induced Pluripotent Stem Cells and Derivative Cells, by Species, Through 2024
Table 32: European Market for Induced Pluripotent Stem Cells and Derivative Cells, by Species, Through 2024
Table 33: Asia-Pacific Market for Induced Pluripotent Stem Cells and Derivative Cells, by Species, Through 2024
Table 34: Global Market for Cell Culture Products for Induced Pluripotent Stem Cells and Derived Cells, by Region, Through 2024
Table 35: Global Market for Induced Pluripotent Stem Cell-Related Products, by Function, Through 2024
Table 36: U.S. Market for Induced Pluripotent Stem Cell-Related Products, by Function, Through 2024
Table 37: Global Market for Induced Pluripotent Stem Cell-Derived Cell Products for Research, by Cell Type, Through 2024
Table 38: Global Market for Induced Pluripotent Stem Cell Products for Academic Research, by Region, Through 2024
Table 39: Major University and Institute Induced Pluripotent Stem Cell Core Facilities, by Location
Table 40: Global Market for Induced Pluripotent Stem Cell Products for Drug Development and Toxicity Testing, by Cell Type, Through 2024
Table 41: Global Market for Induced Pluripotent Stem Cell Products for Drug Development and Toxicity Testing, by Region, Through 2024
Table 42: Major Companies Providing Induced Pluripotent Stem Cell Contract Services, 2019
Table 43: Global Market for Induced Pluripotent Stem Cell Contract Services, by Region, Through 2024
Table 44: Global Market for Induced Pluripotent Stem Cell-Derived Products for Regenerative Medicine, by Cell Type, Through 2024
Table 45: Global Market for Induced Pluripotent Stem Cell Products for Clinical Applications (Including Patient-Specific iPSC Banking), by Region, Through 2024
Table 46: Major Governmental Induced Pluripotent Stem Cell Research Funding, by Region, 2006-October 2019
Table 47: National Institutes of Health Induced Pluripotent Stem Cells Research Funding, 2006-October 2019
Table 48: California Institute of Regenerative Medicine Induced Pluripotent Stem Cell Funding, October 2019
Table 49: U.S. Patents on Induced Pluripotent Stem Cells, 2017-October 2019
Table 50: Shares of Global Patents or Patent Applications on Induced Pluripotent Stem Cells, by Region, 2011-October 2019
Table 51: Distribution of Patents and Patent Applications on Induced Pluripotent Stem Cells, by Patent Office or Country, 2011-October 2019
Table 52: Main Inventors Listed on Global Patents or Patent Applications on Induced Pluripotent Stem Cells, 2011-October 2019
Table 53: Main Applicants Listed on Global Patents or Patent Applications on Induced Pluripotent Stem Cells, 2011-October 2019
Table 54: Global Patents and Patent Applications on Induced Pluripotent Stem Cells, by Year, 2008-October 2019
Table 55: U.S. Patents on Induced Pluripotent Stem Cells, 2009-October 2019
Table 56: Global Patents and Patent Applications Filed with the USPTO on Induced Pluripotent Stem Cells, by Assignee’s Country, October 2019
Table 57: U.S. Patents on Induced Pluripotent Stem Cells, by U.S. State, October 2019
Table 58: Scientific Publications of Induced Pluripotent Stem Cell Research, 2006-October 2019
List of Figures
Summary Figure: Global Market for Induced Pluripotent Stem Cells, by Region, 2018-2024
Figure 1: Global Market Shares of Induced Pluripotent Stem Cell Products, by Region, 2024
Figure 2: U.S. Market Shares of Induced Pluripotent Stem Cell Products, by U.S. State, 2024
Figure 3: Global Market Shares of the Generation of Induced Pluripotent Stem Cells, by Reprogramming Method, 2024
Figure 4: Global Market Shares of the Generation of Induced Pluripotent Stem Cell, by Method, 2024
Figure 5: Global Market Shares of Induced Pluripotent Stem Cell Products, by Application, 2024
Figure 6: U.S. Market Shares of Induced Pluripotent Stem Cell Products, by Application, 2024
Figure 7: Global Market Shares of Induced Pluripotent Stem Cell-Derived Tissue Cells, by Type, 2024
Figure 8: Shares of Major Commercial Suppliers of Induced Pluripotent Stem Cell Products, by Country, 2019
Figure 9: Shares of Major U.S. Commercial Suppliers of Induced Pluripotent Stem Cell Products, by U.S. State, 2019
Figure 10: Shares of Major U.S. Commercial Manufacturers of Induced Pluripotent Stem Cell Products, by Country, 2019
Figure 11: Shares of Major U.S. Commercial Induced Pluripotent Stem Cell Product Manufacturers, by State, 2019
Figure 12: Global Market Shares of Induced Pluripotent Stem Cell-Derived Cells, by Application, 2024
Figure 13: Global Market Shares of Induced Pluripotent Stem Cell-Related Products, by Product Function, 2024
Figure 14: U.S. Market Shares of Induced Pluripotent Stem Cell-Related Products, by Product Function, 2024
Figure 15: Global Market Shares of Induced Pluripotent Stem Cells in Research and Clinical Uses, 2024
Figure 16: Global Market Shares of Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes, by Application, 2024
Figure 17: U.S. Market Shares of Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes, by Application, 2024
Figure 18: European Market Shares of Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes, by Application, 2024
Figure 19: Asia-Pacific Market Shares of Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes, by Application, 2024
Figure 20: Global Market Shares of Induced Pluripotent Stem Cell-Derived Human Hepatocytes, by Application, 2024
Figure 21: U.S. Market Shares of Induced Pluripotent Stem Cell-Derived Human Hepatocytes, by Application, 2024
Figure 22: European Market Shares of Induced Pluripotent Stem Cell-Derived Human Hepatocytes, by Application, 2024
Figure 23: Asia-Pacific Market Shares of Induced Pluripotent Stem Cell-Derived Human Hepatocytes, by Application, 2024
Figure 24: Global Market Shares of Induced Pluripotent Stem Cell-Derived Human Endothelia Cells, by Application, 2024
Figure 25: U.S. Market Shares of Induced Pluripotent Stem Cell-Derived Human Endothelia Cells, by Application, 2024
Figure 26: European Market Shares of Induced Pluripotent Stem Cell-Derived Human Endothelia Cells, by Application, 2024
Figure 27: Asia-Pacific Market Shares of Induced Pluripotent Stem Cell-Derived Human Endothelia Cells, by Application, 2024
Figure 28: Global Market Shares of Induced Pluripotent Stem Cell-Derived Human Neural Cells, by Application, 2024
Figure 29: U.S. Market Shares of Induced Pluripotent Stem Cell-Derived Human Neural Cells, by Application, 2024
Figure 30: European Market Shares of Induced Pluripotent Stem Cell-Derived Human Neural Cells, by Application, 2024
Figure 31: Asia-Pacific Market Shares of Induced Pluripotent Stem Cell-Derived Human Neural Cells, by Application, 2024
Figure 32: Global Market Shares of Induced Pluripotent Stem Cells and Derivative Cells, by Species, 2024
Figure 33: Global Market Shares of Cell Culture Products for Induced Pluripotent Stem Cells and Derived Cells, by Region, 2024
Figure 34: Global Market Shares of Induced Pluripotent Stem Cell-Related Products, by Function, 2024
Figure 35: U.S. Market Shares for Induced Pluripotent Stem Cell-Related Products, by Function, 2024
Figure 36: Global Market Shares of Induced Pluripotent Stem Cell-Derived Cell Products for Research, by Cell Type, 2024
Figure 37: Global Market Shares of Induced Pluripotent Stem Cell Products for Academic Research, by Region, 2024
Figure 38: Global Market Shares of Induced Pluripotent Stem Cell Products for Drug Development and Toxicity Testing, by Cell Type, 2024
Figure 39: Global Market Shares of Induced Pluripotent Stem Cell Products for Drug Development and Toxicity Testing, by Region, 2024
Figure 40: Global Market Shares of Induced Pluripotent Stem Cell Contract Services, by Region, 2024
Figure 41: Global Market Shares of Induced Pluripotent Stem Cell-Derived Products for Regenerative Medicine, by Cell Type, 2024
Figure 42: Global Market Shares of Induced Pluripotent Stem Cells Products for Clinical Applications (Including Patient-Specific iPSC Banking), by Region, 2024
Figure 43: Shares of Major Governmental Induced Pluripotent Stem Cell Research Funding, by Region, 2006-October 2019
Figure 44: Shares of Funding Amount for National Institutes of Health Induced Pluripotent Stem Cell Research, 2006-October 2019
Figure 45: Number of Global Patents and Patent Applications on Induced Pluripotent Stem Cells, 2008-October 2019
Figure 46: Shares of U.S. Patents on Induced Pluripotent Stem Cells, 2009-October 2019
Figure 47: Scientific Publications of Induced Pluripotent Stem Cell Research, 2006-October 2019

Note: Product cover images may vary from those shown

Loading
LOADING...

FEATURED COMPANIES

  • Addgene
  • Bio-Techne
  • EMD Millipore
  • Invivogen
  • Opsis Therapeutics
  • Promega Corp.

Summary

It has been over 10 years since the discovery of induced pluripotent stem cell (iPSC) technology. The market has gradually become an important part of the life sciences industry during recent years. Particularly for the past five years, the global market for iPSCs has experienced rapid growth.

Key Drivers for Market Growth


This report has identified several key drivers for the rapidly growing market:


  • iPSCs hold promising hope for therapeutic solutions for diseases without ethical issues. A series of technical breakthroughs were made in recent years for improving cellular reprogramming, differentiation and large-scale production of GMP- grade iPSCs derived cells toward clinical usability.
  • Advances in genetics such as NGS technologies have promoted the progress on precision medicine, where the availability of iPSCs from a variety of genetic, lifestyle and environmental backgrounds will help make precision healthcare a clinical reality. iPSC banking together with related technologies is developing into a platform for precision and personalized medicine, which is experiencing rapid growth globally.
  • In recent years, several iPSCs clinical trials have been or are going to be launched for a variety of diseases. The first human iPSC clinical trial started in August 2014, and the recent report of the first macular degeneration patient treated with the sheets of retinal pigmented epithelial cells made from iPSCs was encouraging. The progress toward clinical practice will drive the growth of the clinical market and the research market as well.
  • The pharmaceutical industry needs better cell sources such as iPSC-derived functional cells for drug toxicity testing and drug screening.
  • The U.S. government has been encouraging the marketing of stem cells, including iPSCs.
  • The U.S. Food and Drug Administration (FDA) has been authorized to provide orphan drug designations for many of the therapies developed for rare diseases such as Parkinson’s and Huntington’s using stem cells.
  • The provisions of grants from organizations, such as the National Institutes of Health (NIH) and the California Institute for Regenerative Medicine (CIRM) have been encouraging for the research institutes to venture into iPSC research.
  • Rapidly growing medical tourism and contract research outsourcing drive the Asia-Pacific stem cell market.
  • Cellular reprogramming, including iPSC technology, was awarded the 2012 Nobel Prize.
  • New biotechnologies such as CRISPR/Cas genome editing technology are advancing iPSCs into more and better uses. For example, the hypoimmunogenic derivatives of engineered iPSCs have shown lost immunogenicity which would become a potential novel therapy to treat various diseases.
Note: Product cover images may vary from those shown
  • ABM (Applied Biological Materials Inc.)
  • Addgene
  • Allele Biotechnology And Pharmaceuticals Inc.
  • Alstem Llc
  • Applied Stemcell Inc.
  • ATCC
  • Axol Bioscience
  • Bio-Techne
  • Bluerock Therapeutics
  • Bristol-Myers Squibb (Ipierian)
  • Cell Signaling Technology
  • Cellular Dynamics International, A Fujifilm Company
  • Corning Life Sciences
  • Creative Bioarray
  • EMD Millipore
  • Fate Therapeutics
  • Genecopoeia
  • Gentarget Inc.
  • ID Pharma Co., Ltd.
  • Invivogen
  • Lonza Group Ltd.
  • Megakaryon Corp.
  • MTI-Globalstem, A Part Of Thermo Fisher Scientific
  • Ncardia
  • Newcells Biotech
  • Opsis Therapeutics
  • Orig3N Inc.
  • Peprotech
  • Plasticell Ltd.
  • Primorigen Biosciences
  • Promega Corp.
  • Promocell Gmbh
  • Qiagen N.V.
  • Reprocell Inc.
  • Roslin Cell Sciences
  • Sciencell Research Laboratories
  • Sigma-Aldrich, A Part Of Milliporesigma
  • Stemcell Technologies
  • Stemgent Inc., A Reprocell Group Co.
  • System Biosciences Inc.
  • Takara Bio Usa Inc. (Clontech Laboratories)
  • Thermo Fisher Scientific
  • Viacyte Inc.
  • Waisman Biomanufacturing
Note: Product cover images may vary from those shown